These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23829877)

  • 1. Dropped head sign induced by transdermal application of the dopamine agonist rotigotine in parkinsonian syndrome: a case report.
    Dohm CP; Gröschel S; Liman J; Bähr M; Kermer P
    J Med Case Rep; 2013 Jul; 7():174. PubMed ID: 23829877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rotigotine transdermal system for the treatment of Parkinson's disease.
    Pham DQ; Nogid A
    Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
    Ceballos-Baumann A; Häck HJ
    Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramipexole-induced antecollis in Parkinson's disease.
    Suzuki M; Hirai T; Ito Y; Sakamoto T; Oka H; Kurita A; Inoue K
    J Neurol Sci; 2008 Jan; 264(1-2):195-7. PubMed ID: 17826796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials.
    Nomoto M; Iwaki H; Kondo H; Sakurai M
    J Neurol; 2018 Feb; 265(2):253-265. PubMed ID: 29164312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
    Boroojerdi B; Wolff HM; Braun M; Scheller DK
    Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dropped head in Parkinson's disease.
    Fujimoto K
    J Neurol; 2006 Dec; 253 Suppl 7():VII21-26. PubMed ID: 17131224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.
    Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M
    Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
    Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
    Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
    Kim JM; Chung SJ; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
    BMC Neurol; 2015 Feb; 15():17. PubMed ID: 25879416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.
    Sanford M; Scott LJ
    CNS Drugs; 2011 Aug; 25(8):699-719. PubMed ID: 21790211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rotigotine in the treatment of Parkinson's disease. A study on a sample of 150 patients].
    Ruiz-Huete C; Bermejo PE; Terrón C; Anciones B
    Rev Neurol; 2008 Mar 1-15; 46(5):257-60. PubMed ID: 18351563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The phenomenon of disproportionate antecollis in Parkinson's disease and multiple system atrophy.
    van de Warrenburg BP; Cordivari C; Ryan AM; Phadke R; Holton JL; Bhatia KP; Hanna MG; Quinn NP
    Mov Disord; 2007 Dec; 22(16):2325-31. PubMed ID: 17960814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine agonist-induced antecollis in Parkinson's disease.
    Uzawa A; Mori M; Kojima S; Mitsuma S; Sekiguchi Y; Kanesaka T; Kuwabara S
    Mov Disord; 2009 Dec; 24(16):2408-11. PubMed ID: 19890970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
    Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M
    Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rotigotine Transdermal Patch: A Review in Parkinson's Disease.
    Frampton JE
    CNS Drugs; 2019 Jul; 33(7):707-718. PubMed ID: 31243728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
    Kulisevsky J; Pagonabarraga J
    Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
    Zareba G
    Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.